MedTrace Logo

Allograft Fibrosis Following Pediatric Cardiac Transplantation

NCT00328185 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2012-03-16

No results posted yet for this study

Summary

Transplantation is the preferred method of treating many forms of end-stage organ failure. While short-term results have improved, long-term outcomes remain inadequate. Myocardial fibrosis could potentially have an adverse effect on long-term cardiac function. We wish to study the degree of fibrosis to see if we can predict survival following pediatric heart transplantation.

Conditions

  • Children Who Underwent Heart Transplantation Prior to Age 18
  • Received Care at Children's Healthcare of Atlanta

Sponsors & Collaborators

  • Children's Healthcare of Atlanta

    lead OTHER

Principal Investigators

  • Brian E Kogon, MD · Emory University

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00328185 on ClinicalTrials.gov